| Literature DB >> 22855598 |
George Vasmatzis1, Sarah H Johnson, Ryan A Knudson, Rhett P Ketterling, Esteban Braggio, Rafael Fonseca, David S Viswanatha, Mark E Law, N Sertac Kip, Nazan Ozsan, Stefan K Grebe, Lori A Frederick, Bruce W Eckloff, E Aubrey Thompson, Marshall E Kadin, Dragana Milosevic, Julie C Porcher, Yan W Asmann, David I Smith, Irina V Kovtun, Stephen M Ansell, Ahmet Dogan, Andrew L Feldman.
Abstract
Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies of mature T lymphocytes with 5-year overall survival rates of only ∼ 35%. Improvement in outcomes has been stymied by poor understanding of the genetics and molecular pathogenesis of PTCL, with a resulting paucity of molecular targets for therapy. We developed bioinformatic tools to identify chromosomal rearrangements using genome-wide, next-generation sequencing analysis of mate-pair DNA libraries and applied these tools to 16 PTCL patient tissue samples and 6 PTCL cell lines. Thirteen recurrent abnormalities were identified, of which 5 involved p53-related genes (TP53, TP63, CDKN2A, WWOX, and ANKRD11). Among these abnormalities were novel TP63 rearrangements encoding fusion proteins homologous to ΔNp63, a dominant-negative p63 isoform that inhibits the p53 pathway. TP63 rearrangements were seen in 11 (5.8%) of 190 PTCLs and were associated with inferior overall survival; they also were detected in 2 (1.2%) of 164 diffuse large B-cell lymphomas. As TP53 mutations are rare in PTCL compared with other malignancies, our findings suggest that a constellation of alternate genetic abnormalities may contribute to disruption of p53-associated tumor suppressor function in PTCL.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22855598 PMCID: PMC5070713 DOI: 10.1182/blood-2012-03-419937
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113